Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel Free CPIX Stock Alerts

Cumberland Pharmaceuticals (CPIX) Financials

Cumberland Pharmaceuticals logo
$6.62 -0.11 (-1.56%)
As of 12:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Cumberland Pharmaceuticals

Annual Income Statements for Cumberland Pharmaceuticals

This table shows Cumberland Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 0.73 -0.94 -7.98 -6.96 -3.54 -3.34 -3.51 -5.57 -6.28 -6.48 -2.84
Consolidated Net Income / (Loss)		 0.67 -1.00 -8.05 -7.04 -3.55 -3.42 -3.60 -5.65 -6.33 -6.44 -2.86
Net Income / (Loss) Continuing Operations		 0.67 -1.00 -8.05 -11 -9.21 -6.63 -5.60 -5.65 -6.33 -6.44 -2.86
Total Pre-Tax Income 		1.25 -1.33 -3.87 -11 -9.29 -6.57 -5.56 -5.58 -6.28 -6.47 -2.81
Total Operating Income		 1.11 -1.43 -4.08 -11 -9.29 -6.38 -7.68 -5.70 -9.55 -6.43 -2.79
Total Gross Profit		 29 27 34 23 27 29 27 33 33 31 38
Total Revenue		 34 33 41 29 34 37 36 42 40 38 45
Operating Revenue		 33 33 41 29 34 37 36 42 40 38 45
Total Cost of Revenue		 4.97 5.96 7.37 6.02 7.42 8.65 8.81 9.12 6.07 6.59 6.67
Operating Cost of Revenue		 4.97 5.96 7.37 6.02 7.42 8.65 8.81 9.12 6.07 6.59 6.67
Total Operating Expenses		 27 29 38 35 36 35 35 39 43 38 41
Selling, General & Admin Expense		 7.61 8.56 9.65 10 9.97 10 9.78 10 11 11 12
Marketing Expense		 14 15 21 14 15 15 15 17 18 17 19
Research & Development Expense		 3.85 3.19 4.28 7.58 6.87 5.77 5.68 6.69 5.83 4.82 5.57
Amortization Expense		 1.99 2.19 2.44 2.77 4.13 4.43 4.37 5.07 8.10 4.75 4.03
Total Other Income / (Expense), net		 0.14 0.10 0.21 0.37 -0.00 -0.19 2.12 0.12 3.27 -0.03 -0.02
Interest Expense		 0.07 0.11 0.09 0.20 0.25 0.26 0.10 0.59 0.67 0.61 0.50
Interest & Investment Income		 0.21 0.20 0.30 0.56 0.24 0.08 0.03 0.10 0.29 0.33 0.48
Other Income / (Expense), net		 - - - - 0.00 0.00 2.19 0.61 3.65 0.24 0.00
Income Tax Expense		 0.58 -0.33 4.17 0.02 -0.08 0.06 0.03 0.07 0.05 -0.02 0.04
Other Gains / (Losses), net		 - - - - - - - - - 0.00 -0.01
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.06 -0.06 -0.07 -0.08 -0.01 -0.08 -0.10 -0.08 -0.05 0.04 -0.03
Basic Earnings per Share		 $0.04 ($0.06) ($0.50) ($0.45) ($0.23) ($0.22) ($0.24) ($0.38) ($0.44) ($0.46) ($0.19)
Weighted Average Basic Shares Outstanding		 16.72M 16.24M 15.91M 15.61M 15.40M 15.16M 14.90M 14.56M 14.30M 14.06M 14.85M
Diluted Earnings per Share		 $0.04 ($0.06) ($0.50) ($0.45) ($0.23) ($0.22) ($0.24) ($0.38) ($0.44) ($0.46) ($0.19)
Weighted Average Diluted Shares Outstanding		 17.09M 16.24M 15.91M 15.61M 15.40M 15.16M 14.90M 14.56M 14.30M 14.06M 14.85M
Weighted Average Basic & Diluted Shares Outstanding		 18.30M 15.70M 16M 15.50M 15.18M 14.92M 14.84M 14.40M 14.18M 13.97M 14.96M

Quarterly Income Statements for Cumberland Pharmaceuticals

This table shows Cumberland Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -1.05 -6.29 -1.95 -1.09 -1.54 -1.90 1.26 -0.74 -1.94 -1.41
Consolidated Net Income / (Loss)		 -1.06 -6.30 -1.90 -1.10 -1.54 -1.90 1.25 -0.74 -1.95 -1.43
Net Income / (Loss) Continuing Operations		 -1.06 -6.30 -1.90 -1.10 -1.54 -1.90 1.25 -0.74 -1.95 -1.43
Total Pre-Tax Income 		-1.06 -6.28 -1.89 -1.09 -1.53 -1.96 1.25 -0.73 -1.94 -1.39
Total Operating Income		 -1.87 -6.18 -1.87 -1.03 -1.69 -1.84 1.29 -0.75 -1.97 -1.37
Total Gross Profit		 8.32 7.82 6.92 8.14 7.76 8.46 10 8.83 7.30 11
Total Revenue		 10 9.35 8.50 9.85 9.09 10 12 11 8.29 14
Operating Revenue		 10 9.35 8.50 9.85 9.09 10 12 11 8.29 14
Total Cost of Revenue		 1.77 1.53 1.58 1.71 1.32 1.98 1.43 2.01 0.99 2.24
Operating Cost of Revenue		 1.77 1.53 1.58 1.71 1.32 1.98 1.43 2.01 0.99 2.24
Total Operating Expenses		 10 14 8.79 9.16 9.46 10 9.00 9.57 9.27 13
Selling, General & Admin Expense		 2.34 3.44 2.37 2.76 2.68 3.33 2.46 2.87 2.57 4.04
Marketing Expense		 4.74 4.76 4.15 4.25 4.40 4.22 4.23 4.22 4.43 6.21
Research & Development Expense		 1.92 1.26 1.16 1.06 1.31 1.29 1.30 1.47 1.25 1.55
Amortization Expense		 1.18 4.54 1.11 1.10 1.08 1.46 1.01 1.01 1.01 1.01
Total Other Income / (Expense), net		 0.81 -0.10 -0.02 -0.06 0.17 -0.12 -0.04 0.02 0.02 -0.02
Interest Expense		 0.11 0.18 0.12 0.13 0.14 0.22 0.16 0.11 0.11 0.11
Interest & Investment Income		 0.10 0.08 0.10 0.06 0.07 0.11 0.13 0.13 0.13 0.09
Income Tax Expense		 0.01 0.02 0.01 0.01 0.01 -0.06 0.01 0.01 0.01 0.02
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.01 -0.01 0.04 -0.02 0.01 0.00 -0.01 0.01 -0.01 -0.02
Basic Earnings per Share		 ($0.07) ($0.44) ($0.14) ($0.08) ($0.11) ($0.13) $0.08 ($0.05) ($0.13) ($0.09)
Weighted Average Basic Shares Outstanding		 14.28M 14.30M 14.10M 14.12M 14.05M 14.06M 14.94M 14.96M 14.96M 14.85M
Diluted Earnings per Share		 ($0.07) ($0.44) ($0.14) ($0.08) ($0.11) ($0.13) $0.08 ($0.05) ($0.13) ($0.09)
Weighted Average Diluted Shares Outstanding		 14.28M 14.30M 14.10M 14.12M 14.05M 14.06M 15.26M 14.96M 14.96M 14.85M
Weighted Average Basic & Diluted Shares Outstanding		 14.26M 14.18M 14.19M 14.10M 14.04M 13.97M 14.98M 14.96M 14.96M 14.96M

Annual Cash Flow Statements for Cumberland Pharmaceuticals

This table details how cash moves in and out of Cumberland Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -1.66 -3.69 11 -17 0.27 -2.66 2.29 -7.28 -1.44 -0.36 -6.52
Net Cash From Operating Activities		 5.88 0.57 -0.56 3.11 3.06 5.42 6.34 8.45 6.09 -0.61 4.93
Net Cash From Continuing Operating Activities		 5.88 0.57 -0.56 -1.39 -2.46 1.90 4.35 8.45 6.09 -0.61 4.93
Net Income / (Loss) Continuing Operations		 0.67 -1.00 -8.05 -11 -9.21 -6.63 -5.60 -5.65 -6.33 -6.44 -2.86
Consolidated Net Income / (Loss)		 0.67 -1.00 -8.05 -7.04 -3.55 -3.42 -3.60 -5.65 -6.33 -6.44 -2.86
Depreciation Expense		 2.25 2.40 2.65 2.98 4.40 4.75 4.61 5.33 4.94 4.90 4.15
Amortization Expense		 0.05 0.08 0.08 0.10 0.05 0.05 0.03 0.01 0.85 1.17 1.16
Non-Cash Adjustments To Reconcile Net Income		 0.45 1.80 1.34 1.11 1.46 1.33 -1.73 0.41 6.98 1.71 -0.56
Changes in Operating Assets and Liabilities, net		 2.46 -2.71 3.42 5.23 0.85 2.39 7.03 8.35 -0.34 -1.95 3.05
Net Cash From Investing Activities		 -2.34 -3.12 9.51 -28 2.30 -1.76 -0.50 -14 -0.11 0.06 -4.71
Net Cash From Continuing Investing Activities		 -2.34 -3.12 9.51 -28 2.30 -1.76 -0.50 -14 -0.11 0.06 -4.71
Purchase of Property, Plant & Equipment		 -0.14 -0.13 -0.28 -0.46 -0.25 -0.14 -0.10 -0.10 -0.28 -0.07 -0.10
Acquisitions		 -2.56 -2.00 -1.21 -24 -5.77 -1.97 -0.25 -15 -0.17 -0.11 -2.56
Purchase of Investments		 -7.53 -5.47 -2.38 -20 -12 0.00 - - - 0.00 -2.00
Other Investing Activities, net		 - - - 0.00 0.00 0.36 -0.15 1.90 0.35 0.24 -0.05
Net Cash From Financing Activities		 -5.19 -1.15 1.95 7.14 -5.08 -7.12 -3.55 -2.06 -7.42 0.20 -6.75
Net Cash From Continuing Financing Activities		 -5.19 -1.15 1.95 7.14 -5.08 -6.32 -3.55 -2.06 -7.42 0.20 -6.75
Repayment of Debt		 -1.67 0.00 -19 -46 -78 -63 -59 -52 -35 -36 -10
Repurchase of Common Equity		 -5.34 -2.52 -3.75 -3.26 -3.49 -1.99 -1.39 -1.05 -0.74 -0.58 -0.26
Issuance of Debt		 1.70 2.40 25 56 76 59 59 53 31 38 0.00
Issuance of Common Equity		 - - 0.00 0.00 1.00 0.00 - - - 0.00 5.27
Other Financing Activities, net		 0.11 -1.03 0.00 0.20 -1.03 -0.82 -2.17 -2.21 -3.27 -1.72 -1.71
Cash Interest Paid		 0.03 0.02 0.01 0.10 0.20 0.22 0.06 0.52 0.65 0.57 0.44
Cash Income Taxes Paid		 0.05 -0.01 0.02 0.02 0.02 -0.09 -0.00 0.00 0.11 0.02 -0.00

Quarterly Cash Flow Statements for Cumberland Pharmaceuticals

This table details how cash moves in and out of Cumberland Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Change in Cash & Equivalents		 0.26 -0.19 0.23 -1.21 0.13 0.50 -2.86 0.98 -0.89 -3.75
Net Cash From Operating Activities		 1.24 1.04 -2.14 -0.86 0.48 1.90 3.90 0.84 0.19 0.00
Net Cash From Continuing Operating Activities		 1.24 1.04 -2.14 -0.86 0.48 1.90 3.90 0.84 0.19 0.00
Net Income / (Loss) Continuing Operations		 -1.06 -6.30 -1.90 -1.10 -1.54 -1.90 1.25 -0.74 -1.95 -1.43
Consolidated Net Income / (Loss)		 -1.06 -6.30 -1.90 -1.10 -1.54 -1.90 1.25 -0.74 -1.95 -1.43
Depreciation Expense		 1.25 1.23 1.15 1.14 1.12 1.50 1.03 1.03 1.04 1.04
Amortization Expense		 0.24 0.13 0.29 0.29 -0.56 1.15 0.29 0.29 0.29 0.29
Non-Cash Adjustments To Reconcile Net Income		 -1.31 9.24 -0.05 -0.33 0.40 1.69 -0.06 -0.48 -0.23 0.00
Changes in Operating Assets and Liabilities, net		 2.12 -3.26 -1.62 -0.85 1.05 -0.53 1.39 0.74 1.04 0.10
Net Cash From Investing Activities		 -0.10 0.26 -0.06 -0.05 0.19 -0.03 -1.23 0.29 -0.69 -3.07
Net Cash From Continuing Investing Activities		 -0.10 0.26 -0.06 -0.05 0.19 -0.03 -1.23 0.29 -0.69 -3.07
Purchase of Property, Plant & Equipment		 -0.05 -0.05 -0.04 -0.01 -0.02 -0.00 -0.05 -0.03 -0.02 0.00
Acquisitions		 -0.04 -0.04 -0.02 -0.04 -0.03 -0.02 -0.02 0.31 -0.62 -1.07
Net Cash From Financing Activities		 -0.88 -1.49 2.42 -0.31 -0.54 -1.38 -5.53 -0.15 -0.39 -0.68
Net Cash From Continuing Financing Activities		 -0.88 -1.49 2.42 -0.31 -0.54 -1.38 -5.53 -0.15 -0.39 -0.68
Other Financing Activities, net		 -0.46 -1.16 -0.63 -0.18 -0.44 -0.46 -0.51 -0.14 -0.38 -0.68

Annual Balance Sheets for Cumberland Pharmaceuticals

This table presents Cumberland Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 92 93 93 113 105 96 84 93 82 76 77
Total Current Assets		 65 66 69 59 50 50 46 46 36 36 37
Cash & Equivalents		 38 35 45 28 28 25 27 20 18 18 11
Accounts Receivable		 6.08 7.33 8.40 7.84 7.86 12 6.88 13 9.76 12 17
Inventories, net		 4.27 5.37 6.74 12 8.87 11 8.43 9.86 4.61 4.00 6.23
Prepaid Expenses		 1.47 2.71 3.47 2.96 2.76 2.20 3.34 3.08 3.03 2.79 2.45
Plant, Property, & Equipment, net		 0.54 0.46 0.53 0.77 0.75 0.57 0.44 0.28 0.37 0.28 0.26
Total Noncurrent Assets		 27 27 24 53 54 46 38 47 46 39 39
Goodwill		 - - 0.00 0.78 0.88 0.88 0.88 0.91 0.91 0.91 0.91
Intangible Assets		 21 22 21 34 31 28 24 31 23 18 14
Other Noncurrent Operating Assets		 1.89 2.12 2.49 18 22 17 13 15 22 20 25
Total Liabilities & Shareholders' Equity		 92 93 93 113 105 96 84 93 82 76 77
Total Liabilities		 15 20 29 57 53 50 42 57 53 53 52
Total Current Liabilities		 12 15 18 28 24 26 19 29 28 32 37
Accounts Payable		 2.88 8.04 8.98 11 9.99 13 9.64 11 14 14 19
Other Current Liabilities		 - - - - 0.92 1.02 0.97 18 14 13 18
Total Noncurrent Liabilities		 2.69 5.49 12 29 29 24 23 28 25 21 16
Long-Term Debt		 1.70 4.10 9.80 20 19 15 15 16 13 10 5.24
Other Noncurrent Operating Liabilities		 0.99 1.39 1.82 9.32 11 8.92 7.58 12 12 11 10
Total Equity & Noncontrolling Interests		 77 73 64 56 51 47 43 36 29 23 25
Total Preferred & Common Equity		 77 73 64 56 51 47 43 36 30 23 25
Total Common Equity		 77 73 64 56 51 47 43 36 30 23 25
Common Stock		 57 55 52 51 50 49 48 47 47 47 52
Retained Earnings		 20 19 12 4.75 1.21 -2.13 -5.64 -11 -17 -24 -27
Noncontrolling Interest		 -0.07 -0.13 -0.20 -0.27 -0.04 -0.12 -0.21 -0.29 -0.34 -0.31 -0.34

Quarterly Balance Sheets for Cumberland Pharmaceuticals

This table presents Cumberland Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2026 6/30/2025 9/30/2025
Total Assets		 88 82 79 77 71 68 66
Total Current Assets		 42 36 36 35 33 31 30
Cash & Equivalents		 19 19 17 17 11 16 15
Accounts Receivable		 13 11 12 11 14 10 10
Inventories, net		 8.67 4.33 4.30 4.51 5.45 3.22 2.93
Prepaid Expenses		 - 2.68 2.32 1.95 2.07 1.58 1.38
Plant, Property, & Equipment, net		 0.38 0.37 0.34 0.31 0.24 0.30 0.29
Total Noncurrent Assets		 46 45 43 41 38 36 36
Goodwill		 0.91 0.91 0.91 0.91 0.91 0.91 0.91
Intangible Assets		 27 22 20 19 13 16 15
Other Noncurrent Operating Assets		 18 22 21 21 24 20 20
Total Liabilities & Shareholders' Equity		 88 82 79 77 71 68 66
Total Liabilities		 52 54 52 52 50 40 40
Total Current Liabilities		 27 26 25 31 34 24 24
Short-Term Debt		 - - - 5.99 - 0.00 0.00
Accounts Payable		 11 13 13 12 17 13 14
Other Current Liabilities		 17 13 12 13 18 11 10
Total Noncurrent Liabilities		 25 28 28 21 15 16 16
Long-Term Debt		 13 16 16 10 5.24 5.24 5.24
Other Noncurrent Operating Liabilities		 12 12 12 11 9.96 11 11
Total Equity & Noncontrolling Interests		 36 27 26 24 21 28 26
Total Preferred & Common Equity		 36 27 26 25 22 28 26
Total Common Equity		 36 27 26 25 22 28 26
Common Stock		 47 47 47 47 52 51 52
Retained Earnings		 -11 -19 -21 -22 -30 -23 -25
Noncontrolling Interest		 -0.34 -0.30 -0.32 -0.31 -0.33 -0.31 -0.32

Annual Metrics And Ratios for Cumberland Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Cumberland Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 16,452,665.00 16,180,604.00 15,748,137.00 15,527,623.00 15,183,943.00 15,036,923.00 14,809,628.00 14,464,127.00 14,255,700.00 14,042,304.00 14,956,627.00
DEI Adjusted Shares Outstanding		 16,452,665.00 16,180,604.00 15,748,137.00 15,527,623.00 15,183,943.00 15,036,923.00 14,809,628.00 14,464,127.00 14,255,700.00 14,042,304.00 14,956,627.00
DEI Earnings Per Adjusted Shares Outstanding		 0.04 -0.06 -0.51 -0.45 -0.23 -0.22 -0.24 -0.39 -0.44 -0.46 -0.19
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -9.17% -1.47% 24.60% -28.69% 17.19% 8.88% -3.89% 16.75% -5.85% -4.26% 17.57%
EBITDA Growth		 -39.06% -69.21% -229.32% -496.78% 40.22% 67.22% 46.39% 128.92% -148.02% -4.83% 2,134.72%
EBIT Growth		 -68.76% -228.92% -184.79% -173.76% 16.87% 31.29% 13.97% 7.23% -15.91% -4.93% 54.93%
NOPAT Growth		 -73.36% -267.68% -184.79% -173.76% 16.87% 31.29% -20.31% 25.69% -67.48% 32.68% 56.59%
Net Income Growth		 -71.59% -249.59% -701.82% 12.56% 49.61% 3.60% -5.38% -56.82% -12.05% -1.78% 55.54%
EPS Growth		 -71.43% -250.00% -733.33% 10.00% 48.89% 4.35% -9.09% -58.33% -15.79% -4.55% 58.70%
Operating Cash Flow Growth		 -12.20% -90.31% -197.93% 658.12% -1.81% 77.17% 17.13% 33.28% -27.91% -110.05% 905.72%
Free Cash Flow Firm Growth		 47.67% -362.51% 125.45% -4,052.72% 65.05% 93.61% 325.37% -593.85% 134.29% -131.83% 31.58%
Invested Capital Growth		 -1.12% 5.19% -12.74% 66.44% 4.37% -9.60% -17.67% 6.07% -26.82% -16.29% -7.64%
Revenue Q/Q Growth		 -3.71% 3.26% 6.66% -24.55% 26.50% 2.62% -5.12% 1.95% 0.58% 2.94% 7.86%
EBITDA Q/Q Growth		 -19.67% -50.45% 7.48% -153.74% 37.13% 52.43% -213.76% 113.07% -104.02% 97.93% -25.04%
EBIT Q/Q Growth		 -41.34% -357.75% 1.31% -85.25% 22.20% 20.53% -8.30% 34.54% -194.82% 42.47% 14.43%
NOPAT Q/Q Growth		 -45.65% -357.75% 1.31% -85.25% 22.20% 20.53% -51.45% 26.68% -69.01% 40.27% 14.43%
Net Income Q/Q Growth		 -43.66% -852.40% -0.65% -25.17% 26.29% 1.64% -468.26% 20.14% -154.40% 40.58% 14.17%
EPS Q/Q Growth		 -42.86% 0.00% 0.00% -25.00% 25.81% 0.00% -500.00% 0.00% 0.00% 40.26% 17.39%
Operating Cash Flow Q/Q Growth		 -19.37% -46.93% -177.28% 390.91% -48.39% -0.06% 21.12% 24.77% -29.89% 58.54% -27.83%
Free Cash Flow Firm Q/Q Growth		 -26.90% -37.08% -73.40% -564.12% 71.31% -101.43% 103.01% 7.07% -23.51% -13.12% -108.79%
Invested Capital Q/Q Growth		 -2.78% -3.17% 3.47% 77.50% -3.30% 0.00% -14.64% -11.55% -21.11% -14.02% 15.75%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 85.18% 81.96% 82.09% 79.50% 78.42% 76.89% 75.51% 78.29% 84.66% 82.61% 85.02%
EBITDA Margin		 10.16% 3.17% -3.29% -27.57% -14.06% -4.23% -2.36% 0.59% -0.30% -0.33% 5.65%
Operating Margin		 3.32% -4.34% -9.92% -38.07% -27.01% -17.04% -21.34% -13.58% -24.16% -16.99% -6.27%
EBIT Margin		 3.32% -4.34% -9.92% -38.07% -27.01% -17.04% -15.26% -12.12% -14.93% -16.36% -6.27%
Profit (Net Income) Margin		 2.00% -3.04% -19.56% -23.99% -10.31% -9.13% -10.01% -13.45% -16.01% -17.02% -6.43%
Tax Burden Percent		 53.82% 75.21% 207.74% 65.15% 38.17% 52.04% 64.77% 101.23% 100.73% 99.65% 101.90%
Interest Burden Percent		 112.17% 93.14% 94.94% 96.70% 100.03% 102.95% 101.31% 109.57% 106.45% 104.38% 100.69%
Effective Tax Rate		 46.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 2.31% -3.80% -11.26% -24.84% -16.17% -11.43% -15.88% -12.68% -23.83% -20.66% -10.23%
ROIC Less NNEP Spread (ROIC-NNEP)		 2.17% -3.80% 0.77% -27.61% -38.69% -22.03% -32.14% 8.56% -31.69% 26.53% 10.24%
Return on Net Nonoperating Assets (RNNOA)		 -1.46% 2.46% -0.48% 13.06% 9.52% 4.45% 7.83% -1.70% 4.42% -4.21% -1.93%
Return on Equity (ROE)		 0.85% -1.34% -11.75% -11.78% -6.65% -6.98% -8.05% -14.38% -19.41% -24.88% -12.17%
Cash Return on Invested Capital (CROIC)		 3.44% -8.85% 2.35% -74.71% -20.45% -1.34% 3.50% -18.57% 7.14% -2.93% -2.29%
Operating Return on Assets (OROA)		 1.19% -1.55% -4.37% -10.85% -8.55% -6.35% -6.07% -5.74% -6.76% -7.87% -3.66%
Return on Assets (ROA)		 0.72% -1.08% -8.63% -6.84% -3.27% -3.40% -3.98% -6.37% -7.25% -8.19% -3.76%
Return on Common Equity (ROCE)		 0.85% -1.34% -11.78% -11.83% -6.67% -6.99% -8.08% -14.47% -19.60% -25.19% -12.33%
Return on Equity Simple (ROE_SIMPLE)		 0.87% -1.37% -12.55% -12.60% -6.94% -7.28% -8.41% -15.58% -21.39% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 0.60 -1.00 -2.86 -7.82 -6.50 -4.47 -5.37 -3.99 -6.69 -4.50 -1.95
NOPAT Margin		 1.78% -3.04% -6.94% -26.65% -18.91% -11.93% -14.93% -9.51% -16.91% -11.89% -4.39%
Net Nonoperating Expense Percent (NNEP)		 0.14% 0.00% -12.03% 2.77% 22.51% 10.60% 16.26% -21.24% 7.86% -47.20% -20.48%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -15.91% -11.90% -6.56%
Cost of Revenue to Revenue		 14.82% 18.04% 17.91% 20.50% 21.58% 23.11% 24.49% 21.71% 15.34% 17.39% 14.98%
SG&A Expenses to Revenue		 22.70% 25.92% 23.45% 34.59% 29.01% 27.23% 27.18% 24.23% 26.93% 29.38% 26.83%
R&D to Revenue		 11.48% 9.66% 10.40% 25.82% 19.97% 15.42% 15.80% 15.92% 14.75% 12.72% 12.50%
Operating Expenses to Revenue		 81.86% 86.30% 92.01% 117.57% 105.43% 93.93% 96.85% 91.87% 108.82% 99.59% 91.30%
Earnings before Interest and Taxes (EBIT)		 1.11 -1.43 -4.08 -11 -9.29 -6.38 -5.49 -5.09 -5.90 -6.20 -2.79
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 3.40 1.05 -1.36 -8.09 -4.84 -1.59 -0.85 0.25 -0.12 -0.12 2.52
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.13 1.22 1.81 1.68 1.53 0.94 1.62 0.90 0.86 1.46 2.39
Price to Tangible Book Value (P/TBV)		 1.55 1.74 2.72 4.37 4.05 2.47 3.85 6.83 4.20 8.39 5.99
Price to Revenue (P/Rev)		 2.58 2.69 2.82 3.19 2.27 1.18 1.92 0.77 0.65 0.88 1.34
Price to Earnings (P/E)		 118.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.85% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.37 1.58 3.19 1.96 1.67 0.93 1.86 0.89 0.83 1.53 2.89
Enterprise Value to Revenue (EV/Rev)		 1.06 1.30 1.83 2.63 1.99 0.92 1.58 0.68 0.50 0.80 1.19
Enterprise Value to EBITDA (EV/EBITDA)		 10.40 40.86 0.00 0.00 0.00 0.00 0.00 116.76 0.00 0.00 21.05
Enterprise Value to EBIT (EV/EBIT)		 31.85 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 59.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 6.02 75.22 0.00 24.78 22.40 6.37 8.97 3.39 3.23 0.00 10.74
Enterprise Value to Free Cash Flow (EV/FCFF)		 39.74 0.00 126.72 0.00 0.00 0.00 48.05 0.00 9.80 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.02 0.06 0.15 0.36 0.36 0.32 0.35 0.45 0.44 0.68 0.21
Long-Term Debt to Equity		 0.02 0.06 0.15 0.36 0.36 0.32 0.35 0.45 0.44 0.45 0.21
Financial Leverage		 -0.67 -0.65 -0.63 -0.47 -0.25 -0.20 -0.24 -0.20 -0.14 -0.16 -0.19
Leverage Ratio		 1.19 1.24 1.36 1.72 2.04 2.05 2.02 2.26 2.68 3.04 3.24
Compound Leverage Factor		 1.33 1.15 1.29 1.67 2.04 2.11 2.05 2.47 2.85 3.17 3.26
Debt to Total Capital		 2.17% 5.31% 13.29% 26.47% 26.59% 24.24% 26.04% 31.05% 30.41% 40.39% 17.60%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 13.48% 0.00%
Long-Term Debt to Total Capital		 2.17% 5.31% 13.29% 26.47% 26.59% 24.24% 26.04% 31.05% 30.41% 26.91% 17.60%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -0.09% -0.17% -0.27% -0.36% -0.05% -0.19% -0.37% -0.56% -0.82% -0.81% -1.13%
Common Equity to Total Capital		 97.92% 94.86% 86.98% 73.90% 73.47% 75.95% 74.33% 69.51% 70.41% 60.42% 83.53%
Debt to EBITDA		 0.50 3.91 -7.23 -2.47 -3.83 -9.46 -17.65 65.92 -108.33 -123.48 2.08
Net Debt to EBITDA		 -15.00 -43.91 29.72 2.01 2.01 6.15 14.17 -14.48 46.92 21.73 -2.46
Long-Term Debt to EBITDA		 0.50 3.91 -7.23 -2.47 -3.83 -9.46 -17.65 65.92 -108.33 -82.26 2.08
Debt to NOPAT		 2.84 -4.09 -3.43 -2.56 -2.85 -3.36 -2.79 -4.06 -1.91 -3.39 -2.68
Net Debt to NOPAT		 -85.36 45.89 14.10 2.08 1.49 2.18 2.24 0.89 0.83 0.60 3.17
Long-Term Debt to NOPAT		 2.84 -4.09 -3.43 -2.56 -2.85 -3.36 -2.79 -4.06 -1.91 -2.26 -2.68
Altman Z-Score		 4.82 3.87 3.50 1.31 1.23 0.98 1.48 0.67 0.35 0.24 0.66
Noncontrolling Interest Sharing Ratio		 -0.05% -0.13% -0.24% -0.40% -0.29% -0.16% -0.37% -0.64% -0.97% -1.26% -1.37%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.20 4.43 3.88 2.13 2.08 1.95 2.37 1.61 1.28 1.15 1.01
Quick Ratio		 4.74 3.88 3.31 1.59 1.49 1.45 1.76 1.15 1.00 0.94 0.77
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.89 -2.34 0.60 -24 -8.22 -0.53 1.18 -5.85 2.01 -0.64 -0.44
Operating Cash Flow to CapEx		 4,110.70% 435.14% -202.10% 683.26% 1,241.40% 3,845.46% 6,126.07% 8,275.64% 2,166.55% -921.12% 5,038.17%
Free Cash Flow to Firm to Interest Expense		 12.06 -21.98 6.41 -120.12 -33.40 -1.99 12.08 -9.98 3.00 -1.05 -0.88
Operating Cash Flow to Interest Expense		 79.57 5.35 -6.00 15.89 12.41 20.54 64.70 14.43 9.12 -1.01 9.94
Operating Cash Flow Less CapEx to Interest Expense		 77.64 4.12 -8.97 13.57 11.41 20.01 63.64 14.25 8.70 -1.12 9.75
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.36 0.36 0.44 0.29 0.32 0.37 0.40 0.47 0.45 0.48 0.58
Accounts Receivable Turnover		 5.79 4.93 5.23 3.61 4.38 3.70 3.74 4.19 3.45 3.53 3.11
Inventory Turnover		 1.01 1.24 1.22 0.64 0.71 0.89 0.92 1.00 0.84 1.53 1.30
Fixed Asset Turnover		 56.45 65.99 82.85 45.14 45.28 56.64 70.78 115.63 121.34 117.37 164.26
Accounts Payable Turnover		 1.62 1.09 0.87 0.60 0.70 0.74 0.77 0.89 0.49 0.47 0.41
Days Sales Outstanding (DSO)		 63.06 74.09 69.74 100.99 83.34 98.64 97.65 87.06 105.76 103.42 117.43
Days Inventory Outstanding (DIO)		 362.58 295.31 299.84 570.73 515.18 411.47 394.94 366.13 435.39 238.57 279.90
Days Payable Outstanding (DPO)		 224.82 334.27 421.34 608.85 518.55 493.31 477.15 409.49 747.75 774.56 889.12
Cash Conversion Cycle (CCC)		 200.82 35.12 -51.76 62.87 79.96 16.80 15.44 43.70 -206.61 -432.57 -491.79
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 26 27 24 39 41 37 31 32 24 20 18
Invested Capital Turnover		 1.29 1.25 1.62 0.93 0.86 0.96 1.06 1.33 1.41 1.74 2.33
Increase / (Decrease) in Invested Capital		 -0.29 1.34 -3.45 16 1.72 -3.94 -6.56 1.85 -8.69 -3.86 -1.52
Enterprise Value (EV)		 35 43 75 77 68 34 57 29 20 30 53
Market Capitalization		 87 89 116 94 78 44 69 33 26 33 60
Book Value per Share		 $4.67 $4.53 $4.07 $3.60 $3.37 $3.13 $2.89 $2.51 $2.08 $1.63 $1.66
Tangible Book Value per Share		 $3.39 $3.16 $2.71 $1.38 $1.27 $1.20 $1.21 $0.33 $0.43 $0.28 $0.66
Total Capital		 79 77 74 76 70 62 58 52 42 38 30
Total Debt		 1.70 4.10 9.80 20 19 15 15 16 13 15 5.24
Total Long-Term Debt		 1.70 4.10 9.80 20 19 15 15 16 13 10 5.24
Net Debt		 -51 -46 -40 -16 -9.71 -9.75 -12 -3.56 -5.54 -2.69 -6.20
Capital Expenditures (CapEx)		 0.14 0.13 0.28 0.46 0.25 0.14 0.10 0.10 0.28 0.07 0.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.60 0.62 0.90 -4.92 -2.20 -0.45 -0.63 -2.47 -11 -8.03 -11
Debt-free Net Working Capital (DFNWC)		 52 51 51 31 26 24 26 17 7.73 9.93 0.32
Net Working Capital (NWC)		 52 51 51 31 26 24 26 17 7.73 4.83 0.32
Net Nonoperating Expense (NNE)		 -0.07 0.00 5.19 -0.78 -2.96 -1.05 -1.77 1.66 -0.36 1.94 0.91
Net Nonoperating Obligations (NNO)		 -51 -46 -40 -16 -10 -9.75 -12 -3.56 -5.54 -2.69 -6.20
Total Depreciation and Amortization (D&A)		 2.29 2.48 2.73 3.08 4.45 4.80 4.64 5.34 5.79 6.07 5.31
Debt-free, Cash-free Net Working Capital to Revenue		 -1.78% 1.88% 2.20% -16.76% -6.40% -1.21% -1.76% -5.87% -26.77% -21.22% -25.00%
Debt-free Net Working Capital to Revenue		 155.65% 153.68% 123.91% 106.70% 75.64% 64.91% 73.39% 41.16% 19.55% 26.22% 0.71%
Net Working Capital to Revenue		 155.65% 153.68% 123.91% 106.70% 75.64% 64.91% 73.39% 41.16% 19.55% 12.76% 0.71%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.04 ($0.06) ($0.50) ($0.45) ($0.23) ($0.22) ($0.24) ($0.38) ($0.44) ($0.46) ($0.19)
Adjusted Weighted Average Basic Shares Outstanding		 16.72M 16.24M 15.91M 15.61M 15.40M 15.16M 14.90M 14.56M 14.30M 14.06M 14.85M
Adjusted Diluted Earnings per Share		 $0.04 ($0.06) ($0.50) ($0.45) ($0.23) ($0.22) ($0.24) ($0.38) ($0.44) ($0.46) ($0.19)
Adjusted Weighted Average Diluted Shares Outstanding		 17.09M 16.24M 15.91M 15.61M 15.40M 15.16M 14.90M 14.56M 14.30M 14.06M 14.85M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 16.31M 16.01M 15.65M 15.45M 15.18M 14.92M 14.84M 14.40M 14.18M 13.97M 14.96M
Normalized Net Operating Profit after Tax (NOPAT)		 0.60 -1.00 -2.86 -7.82 -6.50 -4.47 -5.37 -3.99 -6.69 -4.50 -1.95
Normalized NOPAT Margin		 1.78% -3.04% -6.94% -26.65% -18.91% -11.93% -14.93% -9.51% -16.91% -11.89% -4.39%
Pre Tax Income Margin		 3.72% -4.04% -9.42% -36.82% -27.02% -17.55% -15.46% -13.29% -15.89% -17.08% -6.31%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 15.05 -13.47 -43.93 -57.05 -37.73 -24.21 -56.01 -8.69 -8.84 -10.23 -5.63
NOPAT to Interest Expense		 8.10 -9.43 -30.75 -39.93 -26.41 -16.94 -54.82 -6.81 -10.01 -7.44 -3.94
EBIT Less CapEx to Interest Expense		 13.12 -14.70 -46.90 -59.38 -38.73 -24.74 -57.06 -8.87 -9.26 -10.34 -5.83
NOPAT Less CapEx to Interest Expense		 6.16 -10.66 -33.72 -42.26 -27.41 -17.48 -55.88 -6.99 -10.44 -7.55 -4.14
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 795.55% -251.08% -46.61% -46.35% -98.55% -58.12% -38.49% -18.64% -11.70% -8.99% -9.20%

Quarterly Metrics And Ratios for Cumberland Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Cumberland Pharmaceuticals' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
DEI Shares Outstanding		 14,371,214.00 14,255,700.00 14,176,529.00 14,191,229.00 14,095,548.00 14,042,304.00 13,968,394.00 14,961,137.00 14,959,937.00 14,956,627.00
DEI Adjusted Shares Outstanding		 14,371,214.00 14,255,700.00 14,176,529.00 14,191,229.00 14,095,548.00 14,042,304.00 13,968,394.00 14,961,137.00 14,959,937.00 14,956,627.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.07 -0.44 -0.14 -0.08 -0.11 -0.14 0.09 -0.05 -0.13 -0.09
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 -11.63% 2.51% -7.88% -9.55% -9.92% 11.57% 37.84% 10.04% -8.73% 31.08%
EBITDA Growth		 -64.58% -173.26% -124.58% -83.92% -302.07% 116.69% 708.53% 43.25% 29.31% -104.60%
EBIT Growth		 -262.04% -171.28% -692.68% -202.19% -39.49% 70.19% 169.12% 27.20% -34.85% 25.56%
NOPAT Growth		 -546.81% -171.28% 11.13% -3,269.28% 9.22% 70.19% 198.29% 27.20% -15.98% 25.56%
Net Income Growth		 -151.22% -156.21% -1,204.25% -227.89% -44.56% 69.82% 165.61% 33.32% -26.81% 24.87%
EPS Growth		 0.00% 0.00% -1,500.00% -233.33% -57.14% 70.45% 157.14% 37.50% -18.18% 30.77%
Operating Cash Flow Growth		 -53.08% -71.41% -50.66% -116.34% -61.55% 83.12% 282.46% 198.61% -60.64% -99.84%
Free Cash Flow Firm Growth		 602.81% 226.64% 53.50% -24.71% 9.79% -41.05% 7.98% 19.29% 1.51% -78.34%
Invested Capital Growth		 -17.95% -26.82% -30.81% -21.90% -23.19% -16.29% -37.16% -32.09% -31.40% -7.64%
Revenue Q/Q Growth		 -7.37% -7.27% -9.15% 15.90% -7.75% 14.86% 12.24% -7.48% -23.48% 64.95%
EBITDA Q/Q Growth		 -82.20% -1,180.31% 91.08% 193.76% -323.68% 189.24% 225.12% -77.93% -210.39% 94.19%
EBIT Q/Q Growth		 -204.00% -491.43% 69.75% 45.07% -41.95% -26.40% 170.14% -157.86% -162.92% 30.23%
NOPAT Q/Q Growth		 -5,862.01% -231.04% 69.75% 45.07% -65.04% -8.71% 199.74% -140.68% -162.92% 30.23%
Net Income Q/Q Growth		 -223.32% -492.73% 69.81% 42.04% -39.39% -23.73% 165.64% -158.90% -165.10% 26.70%
EPS Q/Q Growth		 -216.67% -528.57% 68.18% 42.86% -37.50% -18.18% 161.54% -162.50% -160.00% 30.77%
Operating Cash Flow Q/Q Growth		 -76.38% -15.89% -305.42% 59.95% 155.57% 300.55% 104.69% -78.36% -77.82% -98.38%
Free Cash Flow Firm Q/Q Growth		 -36.28% -17.15% 122.08% -35.78% -7.09% -55.51% 306.79% -1.41% -20.94% -90.51%
Invested Capital Q/Q Growth		 -5.25% -21.11% 4.23% 0.25% -6.82% -14.02% -21.76% -8.88% -5.87% 15.75%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 82.49% 83.64% 81.46% 82.63% 85.44% 81.06% 87.83% 81.44% 88.08% 83.61%
EBITDA Margin		 4.42% -51.50% -5.06% 4.09% -9.92% 7.70% 22.32% 5.32% -7.68% -0.27%
Operating Margin		 -18.51% -66.07% -22.00% -10.42% -18.65% -17.65% 11.03% -6.90% -23.70% -10.02%
EBIT Margin		 -10.36% -66.07% -22.00% -10.42% -16.04% -17.65% 11.03% -6.90% -23.70% -10.02%
Profit (Net Income) Margin		 -10.54% -67.38% -22.39% -11.20% -16.92% -18.22% 10.66% -6.78% -23.50% -10.44%
Tax Burden Percent		 100.66% 100.40% 100.61% 101.05% 100.75% 97.09% 99.55% 100.78% 100.29% 102.62%
Interest Burden Percent		 101.10% 101.58% 101.17% 106.28% 104.68% 106.33% 97.05% 97.60% 98.89% 101.53%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.45% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -15.27% -65.17% -19.78% -9.76% -18.06% -21.47% 22.41% -9.76% -35.17% -16.36%
ROIC Less NNEP Spread (ROIC-NNEP)		 -21.83% -21.70% 22.98% 2.34% -7.98% -6.59% 23.33% -6.25% -25.05% -5.81%
Return on Net Nonoperating Assets (RNNOA)		 2.19% 3.03% -1.01% -0.24% 0.92% 1.05% -3.96% 1.41% 5.65% 1.10%
Return on Equity (ROE)		 -13.08% -62.14% -20.79% -9.99% -17.14% -20.43% 18.45% -8.35% -29.53% -15.26%
Cash Return on Invested Capital (CROIC)		 7.86% 7.14% 13.51% -2.51% -2.12% -2.93% 34.27% 28.16% 25.51% -2.29%
Operating Return on Assets (OROA)		 -4.56% -29.92% -9.99% -4.69% -7.17% -8.50% 5.94% -3.96% -13.72% -5.86%
Return on Assets (ROA)		 -4.64% -30.51% -10.17% -5.04% -7.57% -8.77% 5.74% -3.90% -13.60% -6.10%
Return on Common Equity (ROCE)		 -13.19% -62.75% -20.99% -10.09% -17.33% -20.68% 18.69% -8.45% -29.90% -15.47%
Return on Equity Simple (ROE_SIMPLE)		 -6.91% 0.00% -30.58% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.31 -4.33 -1.31 -0.72 -1.19 -1.29 1.29 -0.52 -1.38 -0.96
NOPAT Margin		 -12.95% -46.25% -15.40% -7.30% -13.05% -12.36% 10.98% -4.83% -16.59% -7.02%
Net Nonoperating Expense Percent (NNEP)		 6.56% -43.46% -42.76% -12.10% -10.09% -14.89% -0.92% -3.51% -10.12% -10.54%
Return On Investment Capital (ROIC_SIMPLE)		 - -10.29% -3.02% -1.71% -2.92% -3.41% 4.85% -1.59% -4.43% -3.22%
Cost of Revenue to Revenue		 17.51% 16.36% 18.54% 17.37% 14.56% 18.94% 12.17% 18.56% 11.92% 16.39%
SG&A Expenses to Revenue		 23.24% 36.77% 27.87% 27.99% 29.45% 31.88% 21.03% 26.53% 31.02% 29.51%
R&D to Revenue		 19.08% 13.52% 13.63% 10.75% 14.38% 12.39% 11.06% 13.55% 15.11% 11.33%
Operating Expenses to Revenue		 101.00% 149.71% 103.46% 93.05% 104.09% 98.71% 76.80% 88.34% 111.78% 93.64%
Earnings before Interest and Taxes (EBIT)		 -1.04 -6.18 -1.87 -1.03 -1.46 -1.84 1.29 -0.75 -1.97 -1.37
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 0.45 -4.82 -0.43 0.40 -0.90 0.80 2.61 0.58 -0.64 -0.04
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.75 0.86 0.87 0.82 0.73 1.46 2.73 1.79 1.79 2.39
Price to Tangible Book Value (P/TBV)		 3.41 4.20 4.71 4.36 4.05 8.39 7.45 4.52 4.58 5.99
Price to Revenue (P/Rev)		 0.69 0.65 0.61 0.57 0.49 0.88 1.44 1.19 1.13 1.34
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.71 0.83 0.85 0.81 0.71 1.53 3.41 2.31 2.30 2.89
Enterprise Value to Revenue (EV/Rev)		 0.54 0.50 0.54 0.53 0.44 0.80 1.29 0.93 0.88 1.19
Enterprise Value to EBITDA (EV/EBITDA)		 7.23 0.00 0.00 0.00 0.00 0.00 18.10 13.64 10.84 21.05
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 2.44 3.23 3.92 0.00 0.00 0.00 27.72 5.47 5.33 10.74
Enterprise Value to Free Cash Flow (EV/FCFF)		 8.10 9.80 5.15 0.00 0.00 0.00 7.68 6.65 7.33 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.36 0.44 0.59 0.62 0.66 0.68 0.25 0.19 0.20 0.21
Long-Term Debt to Equity		 0.36 0.44 0.59 0.62 0.41 0.45 0.25 0.19 0.20 0.21
Financial Leverage		 -0.10 -0.14 -0.04 -0.10 -0.12 -0.16 -0.17 -0.23 -0.23 -0.19
Leverage Ratio		 2.41 2.68 2.70 2.67 2.74 3.04 3.14 2.73 2.84 3.24
Compound Leverage Factor		 2.43 2.72 2.74 2.84 2.86 3.23 3.05 2.66 2.81 3.29
Debt to Total Capital		 26.60% 30.41% 37.17% 38.20% 39.67% 40.39% 19.74% 15.92% 16.88% 17.60%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 14.77% 13.48% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 26.60% 30.41% 37.17% 38.20% 24.91% 26.91% 19.74% 15.92% 16.88% 17.60%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -0.69% -0.82% -0.69% -0.75% -0.76% -0.81% -1.26% -0.94% -1.03% -1.13%
Common Equity to Total Capital		 74.09% 70.41% 63.52% 62.55% 61.09% 60.42% 81.51% 85.02% 84.15% 83.53%
Debt to EBITDA		 4.40 -108.33 -3.92 -3.08 -2.69 -123.48 1.79 1.83 1.56 2.08
Net Debt to EBITDA		 -1.90 46.92 0.60 0.24 0.23 21.73 -1.97 -3.80 -2.96 -2.46
Long-Term Debt to EBITDA		 4.40 -108.33 -3.92 -3.08 -1.69 -82.26 1.79 1.83 1.56 2.08
Debt to NOPAT		 -3.27 -1.91 -2.32 -2.10 -2.13 -3.39 -2.29 -2.50 -2.29 -2.68
Net Debt to NOPAT		 1.41 0.83 0.36 0.16 0.18 0.60 2.52 5.18 4.36 3.17
Long-Term Debt to NOPAT		 -3.27 -1.91 -2.32 -2.10 -1.34 -2.26 -2.29 -2.50 -2.29 -2.68
Altman Z-Score		 0.74 0.34 0.47 0.49 0.29 0.43 0.73 0.98 0.79 0.72
Noncontrolling Interest Sharing Ratio		 -0.82% -0.97% -0.97% -1.02% -1.07% -1.26% -1.31% -1.17% -1.25% -1.37%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 1.53 1.28 1.37 1.44 1.13 1.15 0.95 1.30 1.23 1.01
Quick Ratio		 1.14 1.00 1.10 1.17 0.93 0.94 0.73 1.10 1.05 0.77
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 5.27 4.37 9.70 6.23 5.79 2.57 10 7.43 5.88 0.56
Operating Cash Flow to CapEx		 2,326.88% 2,136.96% -5,133.58% -11,920.59% 3,091.90% 83,426.11% 8,185.00% 3,185.84% 786.87% 0.00%
Free Cash Flow to Firm to Interest Expense		 47.89 24.43 81.85 49.31 42.14 11.53 63.95 67.84 53.56 4.94
Operating Cash Flow to Interest Expense		 11.23 5.82 -18.03 -6.77 3.46 8.53 23.80 7.70 1.71 0.03
Operating Cash Flow Less CapEx to Interest Expense		 10.75 5.55 -18.38 -6.83 3.35 8.52 23.51 7.46 1.49 0.03
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.44 0.45 0.45 0.45 0.45 0.48 0.54 0.57 0.58 0.58
Accounts Receivable Turnover		 2.82 3.45 3.08 3.17 3.07 3.53 3.30 3.84 3.80 3.11
Inventory Turnover		 0.74 0.84 0.88 0.86 0.93 1.53 1.32 1.79 1.72 1.30
Fixed Asset Turnover		 90.58 121.34 107.20 104.75 106.71 117.37 135.39 132.53 136.37 164.26
Accounts Payable Turnover		 0.64 0.49 0.53 0.56 0.54 0.47 0.43 0.52 0.49 0.41
Days Sales Outstanding (DSO)		 129.27 105.76 118.34 115.14 118.73 103.42 110.65 95.16 96.12 117.43
Days Inventory Outstanding (DIO)		 490.55 435.39 414.22 422.30 391.79 238.57 277.36 203.86 212.20 279.90
Days Payable Outstanding (DPO)		 567.00 747.75 693.75 649.37 680.00 774.56 839.69 703.13 738.01 889.12
Cash Conversion Cycle (CCC)		 52.81 -206.61 -161.20 -111.93 -169.48 -432.57 -451.68 -404.11 -429.68 -491.79
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 30 24 25 25 23 20 16 17 16 18
Invested Capital Turnover		 1.18 1.41 1.28 1.34 1.38 1.74 2.04 2.02 2.12 2.33
Increase / (Decrease) in Invested Capital		 -6.58 -8.69 -11 -6.95 -6.97 -3.86 -9.19 -7.95 -7.25 -1.52
Enterprise Value (EV)		 21 20 21 20 16 30 53 39 36 53
Market Capitalization		 27 26 24 22 18 33 59 50 47 60
Book Value per Share		 $2.50 $2.08 $1.94 $1.86 $1.76 $1.63 $1.55 $1.87 $1.75 $1.66
Tangible Book Value per Share		 $0.55 $0.43 $0.36 $0.35 $0.32 $0.28 $0.57 $0.74 $0.68 $0.66
Total Capital		 49 42 43 42 41 38 27 33 31 30
Total Debt		 13 13 16 16 16 15 5.24 5.24 5.24 5.24
Total Long-Term Debt		 13 13 16 16 10 10 5.24 5.24 5.24 5.24
Net Debt		 -5.58 -5.54 -2.46 -1.24 -1.37 -2.69 -5.77 -11 -9.96 -6.20
Capital Expenditures (CapEx)		 0.05 0.05 0.04 0.01 0.02 0.00 0.05 0.03 0.02 -0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.07 -11 -8.77 -6.51 -7.33 -8.03 -13 -8.85 -9.57 -11
Debt-free Net Working Capital (DFNWC)		 14 7.73 9.78 11 10 9.93 -1.70 7.23 5.63 0.32
Net Working Capital (NWC)		 14 7.73 9.78 11 4.15 4.83 -1.70 7.23 5.63 0.32
Net Nonoperating Expense (NNE)		 -0.24 1.98 0.59 0.38 0.35 0.61 0.04 0.21 0.57 0.47
Net Nonoperating Obligations (NNO)		 -5.58 -5.54 -2.46 -1.24 -1.37 -2.69 -5.77 -11 -9.96 -6.20
Total Depreciation and Amortization (D&A)		 1.49 1.36 1.44 1.43 0.56 2.65 1.32 1.32 1.33 1.33
Debt-free, Cash-free Net Working Capital to Revenue		 -10.34% -26.77% -22.58% -17.23% -19.92% -21.22% -30.93% -21.05% -23.18% -25.00%
Debt-free Net Working Capital to Revenue		 36.73% 19.55% 25.19% 28.65% 27.56% 26.22% -4.14% 17.19% 13.64% 0.71%
Net Working Capital to Revenue		 36.73% 19.55% 25.19% 28.65% 11.28% 12.76% -4.14% 17.19% 13.64% 0.71%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.44) ($0.14) ($0.08) ($0.11) ($0.13) $0.08 ($0.05) ($0.13) ($0.09)
Adjusted Weighted Average Basic Shares Outstanding		 14.28M 14.30M 14.10M 14.12M 14.05M 14.06M 14.94M 14.96M 14.96M 14.85M
Adjusted Diluted Earnings per Share		 $0.00 ($0.44) ($0.14) ($0.08) ($0.11) ($0.13) $0.08 ($0.05) ($0.13) ($0.09)
Adjusted Weighted Average Diluted Shares Outstanding		 14.28M 14.30M 14.10M 14.12M 14.05M 14.06M 15.26M 14.96M 14.96M 14.85M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 14.26M 14.18M 14.19M 14.10M 14.04M 13.97M 14.98M 14.96M 14.96M 14.96M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.31 -4.33 -1.31 -0.72 -1.19 -1.29 1.29 -0.52 -1.38 -0.96
Normalized NOPAT Margin		 -12.95% -46.25% -15.40% -7.30% -13.05% -12.36% 10.98% -4.83% -16.59% -7.02%
Pre Tax Income Margin		 -10.47% -67.11% -22.25% -11.08% -16.79% -18.77% 10.70% -6.73% -23.44% -10.18%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -9.49 -34.56 -15.77 -8.13 -10.61 -8.25 7.89 -6.82 -17.92 -12.14
NOPAT to Interest Expense		 -11.87 -24.19 -11.04 -5.69 -8.63 -5.78 7.85 -4.78 -12.54 -8.50
EBIT Less CapEx to Interest Expense		 -9.97 -34.83 -16.12 -8.18 -10.72 -8.26 7.60 -7.07 -18.13 -12.14
NOPAT Less CapEx to Interest Expense		 -12.35 -24.47 -11.39 -5.75 -8.75 -5.79 7.56 -5.02 -12.76 -8.50
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -29.79% -11.70% -9.53% -7.45% -6.18% -8.99% -11.92% -15.39% -10.84% -9.20%

Financials Breakdown Chart

Key Financial Trends

Cumberland Pharmaceuticals (NASDAQ: CPIX) showed a sharp improvement in revenue through 2025, but profitability remained under pressure and the balance sheet continues to carry meaningful leverage. The latest quarter suggests the business can generate solid top-line growth, yet expenses are still high enough to keep the company in the red.

  • Revenue improved strongly in 2025. Q4 2025 revenue rose to $13.7 million from $10.4 million in Q4 2024, and Q3 2025 revenue was also up year over year at $8.3 million versus $9.1 million in Q3 2024, showing a generally stronger sales trend versus 2024.
  • Gross profit expanded as sales grew. Q4 2025 gross profit was $11.4 million, with Q3 2025 gross profit at $7.3 million, reflecting decent underlying product economics despite higher costs.
  • Operating cash flow turned positive in the latest quarter. Q4 2025 generated a small $3,024 in operating cash flow, an improvement from the more modest but still positive Q3 2025 operating cash flow of $187,180 after a weak Q2.
  • Cash balance remains sizable. The company ended Q3 2025 with $15.2 million in cash and equivalents, giving it some liquidity cushion even as profitability remains weak.
  • Depreciation and amortization continue to support reported cash flow. Non-cash charges remain large, which helps cushion cash flow in quarters when net income is negative.
  • Equity has improved from a year ago. Total common equity was $26.1 million at Q3 2025, up from $24.8 million at Q3 2024, helped by retained earnings recovery from the prior year’s heavier losses.
  • The company is still losing money. Q4 2025 net loss was $1.4 million, and Q3 2025 net loss was $1.9 million, so the business has not yet returned to sustained profitability.
  • Operating expenses remain too high relative to revenue. In Q4 2025, operating expenses of $12.8 million exceeded gross profit of $11.4 million, leading to a $1.4 million operating loss.
  • Marketing spend is especially heavy. Q4 2025 marketing expense was $6.2 million, one of the biggest cost items and a major reason the company remains unprofitable.
  • Leverage is still a concern. Q3 2025 balance sheet debt included $5.2 million of long-term debt and $24.3 million of current liabilities, with total liabilities of $40.1 million versus $25.8 million in equity and noncontrolling interests.

Bottom line: CPIX appears to be improving on the revenue side, but investors should still focus on whether the company can convert that growth into operating leverage. Until marketing and overhead come down relative to sales, profitability may remain inconsistent. The balance sheet is not distressed, but debt and liabilities still matter given the ongoing losses.

07/31/26 12:03 PM ETAI Generated. May Contain Errors.

Cumberland Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Cumberland Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Cumberland Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$2.86 million in 2025, falling from $671.11 thousand in 2015. The previous period was -$6.44 million in 2024. Find out what analysts predict for Cumberland Pharmaceuticals in the coming months.

Cumberland Pharmaceuticals' total operating income in 2025 was -$2.79 million, based on the following breakdown:
  • Total Gross Profit: $37.85 million
  • Total Operating Expenses: $40.65 million

Over the last 10 years, Cumberland Pharmaceuticals' total revenue changed from $33.52 million in 2015 to $44.52 million in 2025, a change of 32.8%.

Cumberland Pharmaceuticals' total liabilities were at $52.28 million at the end of 2025, a 1.4% decrease from 2024, and a 246.2% increase since 2015.

In the past 10 years, Cumberland Pharmaceuticals' cash and equivalents has ranged from $11.44 million in 2025 to $45.41 million in 2017, and is currently $11.44 million as of their latest financial filing in 2025.

Over the last 10 years, Cumberland Pharmaceuticals' book value per share changed from 4.67 in 2015 to 1.66 in 2025, a change of -64.4%.


Related Companies

Financial statements for NASDAQ:CPIX last updated on 7/14/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel